What Coltalin-ND treats: Main Uses and Benefits

Coltalin-ND is a combination product applicable within clinical settings that involve acute or disruptive symptom patterns related to upper respiratory illness. The product category is relevant for managing the simultaneous presence of fever, pain, and congestion in situations where patients experience these symptoms.

---

Simultaneous Management of Pain, Fever, and Congestion

This medication is applied across therapeutic domains where additional symptomatic support is needed for conditions such as the common cold and flu. It helps address symptom clusters that may become intense or disruptive, including headache, minor aches, fever, nasal congestion, and sinus pressure. The key benefit is that it provides support that helps ease the overall symptom burden, and may contribute to better day-to-day comfort during symptomatic periods.

Supportive Relief for Active Daytime Functioning

Relevant when supportive symptom management is appropriate during the day, this non-drowsy formulation is often used when symptoms intensify and supportive relief is needed but alertness must be maintained. It is considered relevant for maintaining functional stability and may assist patients to cope more steadily with symptom fluctuations, providing supportive relief when symptoms interfere with routine activities.

---

“The specific non-drowsy formulation is relevant in situations where patients seek relief from multiple cold symptoms and need to support their alertness and routine activities.”

---

Quick Fact: Relief for Dual Symptom Domains

Symptom Domain	Primary Symptom Relief	Benefit Context
Systemic Discomfort	Fever, Headache, Minor Aches	Contributes to easing overall physical discomfort
Nasal Obstruction	Congestion, Sinus Pressure	Helps address symptoms that interfere with comfortable breathing

Regulatory References

1. DailyMed NIH Label Information

Eligibility: Who Can and Cannot Use Coltalin-ND?

Coltalin-ND, an upper respiratory combination product, is subject to official population eligibility rules defined by government regulatory agencies. These rules govern who is permitted to use the medicine and who is strictly excluded.

---

Contraindications and Prohibitions

The medicine is contraindicated and must not be used in several key populations, including individuals with a known hypersensitivity or allergy to Acetaminophen, Phenylephrine, or any components of the formulation. It is strictly prohibited for patients currently taking or who have recently stopped (within 14 days) a Monoamine Oxidase Inhibitor (MAOI). Furthermore, use is forbidden if a patient is simultaneously taking any other product containing acetaminophen.

---

Age and Conditional Use

Category	Regulatory Status
Approved Age	Adults and Children 12 years of age and older
Pediatric Use	Do not use in children under 12 years of age.
Pregnancy/Lactation	Ask a health professional before use.

Eligibility is limited for individuals with certain pre-existing medical conditions. Patients with Heart Disease, High Blood Pressure, Diabetes, Glaucoma, Severe Hepatic Impairment, or Thyroid Disease must consult a health professional before use. This requirement also extends to those who consume three or more alcoholic drinks daily or have difficulty urinating due to an enlarged prostate, due to increased risks documented in the official labeling.

Interactions with other medicines and products

Official regulatory information for Coltalin-ND establishes specific constraints regarding co-administration with other substances to mitigate the risks of toxicity and exaggerated effects.

Interaction-Related Restrictions

Classification	Interacting Substance/Class	Constraint/Requirement
Contraindicated	Any other product containing acetaminophen	Do not use; increases risk of severe liver damage.
Contraindicated	Monoamine Oxidase Inhibitors (MAOIs)	Do not use; maintain a 2-week washout period after stopping the MAOI.
High Risk	Alcoholic beverages	Avoid; concurrent consumption with 3 or more daily drinks increases the risk of severe liver damage.

Use with Caution

Consultation with a healthcare professional is required before combining Coltalin-ND with certain medicinal products due to potential altered effects or increased side effects:

• Warfarin (a blood thinner): Requires professional guidance due to the potential for altered effects.
• Tranquilizers or Sedatives: May cause additive drowsiness or increase central nervous system depression. This effect is a primary concern when combined with alcohol, sedatives, or tranquilizers.

Specific warnings note that the co-administration with other acetaminophen-containing products or alcohol may lead to severe liver damage in adults and children. In children, a specific constraint notes that taking more than five doses within 24 hours of this product or other acetaminophen products is linked to the increased risk of liver toxicity. The risk of excitability, a known interaction-related effect, is noted to be especially relevant in children.

Coltalin-ND's pharmacodynamic mechanism arises from the distinct actions of its active components. The Acetaminophen component affects central pathways within the nervous system. It is understood to modulate ascending nociceptive signaling by activating descending serotonergic inhibitory pathways and engaging the hypothalamic heat-regulating center. This interaction reduces prostaglandin-mediated elevation of the body's thermoregulatory set point.

Simultaneously, Phenylephrine functions as a direct agonist at alpha1-adrenergic receptors. Its binding initiates a cascade of intracellular events in vascular smooth muscle, notably in the nasal mucosa, resulting in vasoconstriction. The resulting physiological effect is localized reduction in blood flow.

If included, Chlorpheniramine operates as an antagonist at H1 receptors, thereby inhibiting the binding of histamine, a critical inflammatory mediator. This action suppresses downstream signaling sequences associated with histamine release, resulting in physiological modulation of peripheral inflammatory responses.

How to Use Coltalin-ND

Coltalin-ND is an oral tablet for which administration is standardized according to established product labeling. The medicine is intended for short-term, as-needed use, with a defined set of instructions governing the route, dosage, frequency, and duration of self-treatment.

---

Administration and Standard Dosage Regimens

The standard approach for administration is the oral route, where the solid tablet is swallowed. For adults and children 12 years and over, the dosage is two tablets per dose. This regimen is to be repeated every 4 hours while symptoms persist, but the total intake must not exceed 12 tablets in a 24-hour period.

A separate, reduced dosing protocol is specified for younger populations. Children 6 to under 12 years are instructed to take one tablet per dose, also at a 4-hour interval. The maximum dose for this group is restricted to 5 tablets in 24 hours. Use for children under 6 years requires consultation with a healthcare professional.

---

Procedural and Time Constraints

The use of this combination product is subject to parameters focused on compliance and prevention of misuse. A mandatory co-administration restriction prohibits the simultaneous use of Coltalin-ND with any other drug, prescription or non-prescription, that contains acetaminophen. Furthermore, the label defines limits on the duration of use: self-treatment for pain or nasal congestion should not exceed 7 days, and fever should not be treated for more than 3 days without seeking medical guidance. These parameters structure the appropriate, limited context for the medicine’s use.

Research Evidence / Overview of Studies for Coltalin-ND

Evidence for Symptomatic Relief of the Common Cold

Research examined the components of Coltalin-ND in studies exploring how symptoms change over time when individuals experience conditions associated with acute or disruptive episodes, like the common cold. These studies, often in the form of short-term Randomized Controlled Trials (RCTs), were applied in studies examining patient-reported experiences related to a variety of symptoms. This research contributes to the broader evidence landscape related to symptom management in conditions associated with acute or disruptive episodes.

Studies on Relief from Pain and Fever

The analgesic component, Acetaminophen, was evaluated in research that explores short-term symptom changes, focusing on outcomes related to physical discomfort, which includes headache, minor body aches, and body temperature. Studies monitored how symptoms evolved in the observed populations, with findings describing patterns observed in the studies related to these measurements. Research highlights changes measured during the study period for these outcomes related to physical discomfort. The evidence base for this component has been studied extensively for outcomes related to fever and pain, and contributes to understanding symptom patterns in conditions characterized by these symptoms.

Studies on Relief from Nasal Congestion and Sinus Pressure

The decongestant component was studied for outcomes capturing phases of heightened symptom activity, such as nasal congestion and sinus pressure. Research examined temporary physiological imbalance in the nasal passages. Studies reported how symptoms evolved in the observed populations during episodes where symptoms become more noticeable. However, for the oral decongestant Phenylephrine, the findings were mixed across some study protocols, and the certainty remains low regarding the consistency of results across all settings. Research describes the structure of evidence derived from settings with varying symptom burdens.

Evidence for Non-Drowsy Functional Support

The non-drowsy nature of the formulation was observed in studies evaluating daily-life functioning. Research explored the use of the product in situations where outcomes reflecting daily functioning or activity level are important for patients. Evidence contributes to understanding symptom patterns in conditions marked by functional limitations, with findings that describe patterns related to how patients reported their experience during periods of increased symptom activity.

Research on Long-Term Outcomes and Follow-up Duration

The research exploring short-term symptom changes typically defined follow-up durations over limited periods, often focused on single-dose effects (hours) or the duration of acute treatment, which is usually up to 4–7 days. Long-term effects are not fully established for this type of acute combination product, as the evidence derived from settings with varying symptom burdens is focused on temporary relief. This section will describes what has been studied and where data are still emerging regarding outcomes or use beyond the acute treatment period.

Evidence in Special Populations

The research describes that the populations studied were primarily Adults and Adolescents presenting with typical cold symptoms. Data for certain groups remain insufficient, including patients with significant or uncompensated chronic conditions. The evidence quality varies across studies, and results apply only to the populations studied.

Key Limitations and Uncertainties in the Research

The available evidence for Coltalin-ND's components, while providing context for short-term symptom patterns, has limitations. Follow-up durations were typically short, and sample sizes were modest in some trials. Furthermore, the evidence quality varies across studies, particularly regarding the consistency of the decongestant component’s measured effect. Evidence highlights what is known—and what is still uncertain—including the fact that comparative evidence against all other combination products is often lacking. The study results reflect the specific conditions under which they were conducted, and data for certain groups remain insufficient. The evidence contributes to understanding symptom patterns rather than providing conclusive long-term outcomes.

Key Studies & References

1. DailyMed: Acetaminophen and Phenylephrine HCl Tablet Label Information (Example Non-Drowsy Combination Product)

Common questions about Coltalin-ND (FAQ)

---

Q: Is Coltalin-ND the same type of medicine as other common cold treatments?

A: Official classification documents describe Coltalin-ND as an Upper Respiratory Combination product. This means it is formulated to deliver two or more types of active ingredients (like a pain reliever and a decongestant) in a single dose. This combination feature differentiates it from products that contain only one active ingredient.

---

Q: Is it common to feel restless or jumpy after taking Coltalin-ND?

A: Regulatory warnings note the potential for nervousness or sleeplessness as possible adverse reactions related to the nervous system. The official labeling describes these effects as possible, but consumer-facing information does not typically provide a specific frequency rate to state how common these reactions are.

---

Q: What are the most frequently reported side effects in official documents?

A: Regulatory documents list several key potential adverse reactions, including the serious risk of severe liver damage associated with misuse. Other potential effects listed are nervousness, dizziness, and sleeplessness. Official labels generally list the most serious potential risks but do not typically provide a public ranking of which are the most frequently reported.

---

Q: How long does the effect of a single dose of Coltalin-ND generally last?

A: The official administration instructions define the dosing frequency as every 4 hours while symptoms persist. This four-hour interval is the regulatory standard used for dosing, reflecting the studied duration of action for the active ingredients.

---

Q: Is Coltalin-ND appropriate for use by elderly individuals?

A: General use is approved for adults. However, the official label advises specific cautions for people with pre-existing chronic conditions, such as heart disease or high blood pressure, which may be more prevalent in the elderly. Official documents indicate that consultation with a health professional is necessary before use under these conditions.

---

Q: Is Coltalin-ND contraindicated for people with kidney or liver issues?

A: The safety profile highlights the serious risk of severe liver damage tied to the acetaminophen component. Specific regulatory guidance states that consultation with a health professional is necessary for severe hepatic impairment. Warnings regarding kidney impairment are generally noted in professional documents.

---

Q: What are the listed inactive ingredients in Coltalin-ND?

A: Official labeling, such as that provided by the NIH DailyMed, lists the specific inactive ingredients used in the final tablet formulation. The inactive ingredients are listed in the official labeling and may include excipients, colorants, and other components.

---

Q: Does the product label specify how to handle accidental overdose symptoms?

A: Official labeling states that administration should be stopped immediately and professional advice sought if symptoms worsen, new effects occur, or if an overdose is suspected. This immediate action is crucial due to the risk of severe liver damage associated with the acetaminophen component.

---

Q: Is it true that Coltalin-ND contains pseudoephedrine?

A: The official labeling explicitly lists the nasal decongestant as Phenylephrine Hydrochloride. This is a different active ingredient from pseudoephedrine, though both function as decongestants.

---

Q: Does Coltalin-ND help with a sore throat, or just congestion?

A: Official labels for combination products containing Acetaminophen often include relief for minor aches, pain, and sore throat as part of the intended uses. This is in addition to the relief of nasal congestion provided by the second active ingredient.

---

Q: Is dry mouth a known or listed side effect of Coltalin-ND?

A: Dry mouth is an adverse effect that is listed in the official documents for certain active ingredients often found in cold products, such as the antihistamine component. This information is based on the known pharmacological profile of the ingredients.

---

Q: Is there a regulatory warning about operating machinery while using Coltalin-ND?

A: Official warnings caution users about potential central nervous system (CNS) effects such as dizziness, nervousness, and sleeplessness. These effects are noted in the labeling as potentially impairing a person’s ability to safely operate machinery.

---

Q: Does the medicine interact with caffeine or similar stimulants?

A: Regulatory documents caution about combining sympathomimetic agents, like the decongestant Phenylephrine, with other CNS stimulants, including caffeine. This is due to the potential risk of an increase in heart rate or blood pressure when these substances are combined.

---

Q: Are there any specific foods or dietary supplements that are officially advised to be avoided?

A: The official label provides specific, high-risk warnings regarding the consumption of alcohol due to the severe liver damage risk. For other foods or general supplements, the label typically includes a general statement recommending consultation with a health professional.

---

Q: How quickly does Coltalin-ND typically start to show noticeable effects?

A: Official research focuses on symptom changes over limited periods (within hours) to determine short-term efficacy. This research indicates that the medication is intended to have a relatively rapid onset of action, with effects measurable shortly after administration.

---

Q: Where can I access the official prescribing information or patient information leaflet for Coltalin-ND?

A: Official prescribing information or patient leaflets are publicly accessible through regulatory repositories maintained by government bodies. These sources include the NIH DailyMed or the website of the relevant national drug agency (e.g., FDA, EMA).

---

Q: Why is Coltalin-ND sometimes kept behind the pharmacy counter?

A: The requirement for some cold products to be kept behind the pharmacy counter is generally due to government regulations. These rules are put in place to govern the sale of specific decongestant ingredients to limit potential misuse.

---

Q: What is the half-life of the active ingredient(s) in Coltalin-ND?

A: Pharmacokinetic data, such as the half-life of the active ingredients, is factual information included in the Clinical Pharmacology section of official regulatory documents. This value is used by professionals to understand the duration of the drug’s presence in the body.

---

Q: Do regulatory documents advise taking Coltalin-ND with or without food?

A: Official administration instructions specify whether the product can be taken with or without food. This instruction is based on whether food might affect the absorption or tolerability of the active ingredients.

---

Q: Is Coltalin-ND available in a generic version?

A: Regulatory bodies, such as the FDA via the Orange Book, maintain public lists detailing whether therapeutically equivalent generic versions of a branded product are approved and available. This information confirms the availability status of generic equivalents.

---

Q: Can Coltalin-ND be used for non-cold related allergy symptoms?

A: The official uses section for combination products often includes symptoms related to both the common cold and hay fever or other upper respiratory allergies. This is due to the presence of both an antihistamine and a decongestant in the product.

---

Q: Is there a warning about potential interactions with herbal supplements?

A: Official labels include a general statement recommending consultation with a healthcare professional regarding all other medications, including vitamins and herbal products, before use. This general caution is recommended due to the potential for undocumented interactions.

---

Q: Is Coltalin-ND considered a prescription-only medicine in any jurisdiction?

A: The regulatory classification of the drug (e.g., OTC, Prescription, Behind-the-Counter) is a public status determined and published by the relevant government agencies in each jurisdiction. This status defines how the product can be legally sold and accessed.

---

Q: How is the safety of Coltalin-ND monitored after it is made available to the public?

A: Regulatory agencies monitor product safety through established pharmacovigilance systems after a product is released. These systems collect and evaluate reports of adverse events and utilize required post-market surveillance studies to ensure ongoing safety.

---

How to Store and Dispose of Coltalin-ND?

Official regulatory documents define specific environmental and handling requirements to maintain the stability and safety of this medication.

Storage Requirement	Official Condition
Temperature Range	Store below 25 C (77 F).
Environmental Control	Keep tightly sealed in a dry place, away from direct sunlight.
Child Safety	Keep out of reach of children.

For disposal, the product is not on the U.S. Food and Drug Administration's official flush list. Unused or expired Coltalin-ND should be returned to a drug take-back program whenever available. If no take-back option exists, the official guidance is to mix the product with an undesirable substance (such as dirt or used coffee grounds), seal it in a container, and dispose of it in the household trash.